| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Date of Report (Date of earliest event reported): November 16, 2026 |
| 29 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Resubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor |
| 28 Sep 2026 |
8-K: Other Events
On September 3, 2026, a securities class action lawsuit was filed in United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. (the “Company”) and certain of its officers. This action alleg... |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
- Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor |
| 02 Jul 2026 |
8-K: Other Events
The Company had an ending cash balance of approximately $61.4 million as of June 30, 2026. |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 19, 2025, Unicycive Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 14,964,159 shares of common stock, constituting a quorum, were represented in person or by valid pr... |
| 05 Jun 2026 |
8-K: Entry into a Material Definitive Agreement
As previously reported, Unicycive Therapeutics, Inc. (the “Company”) entered into a Sales Agreement, dated November 13, 2024, with Guggenheim Securities, LLC, as sales agent (the “Agent”) as amended by Amendment No. 1 to Sales Agreement ... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 |
| 06 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition
Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 |
| 14 Nov 2025 |
8-K: Other Events
A t-The-Market Offering pursuant to Registration Statement on Form S-3 |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
- Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end |
| 28 Oct 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Cash runway into 2027, which is expected to support application resubmission, potential FDA approval, and launch of OLC |
| 18 Aug 2025 |
8-K: Other Events
On August 15, 2025, Unicycive Therapeutics, Inc. (the “Company”) became aware of a lawsuit purporting to be a securities class action which was filed in United States District Court for the Northern District of California against the Com... |
| 15 Aug 2025 |
8-K: Other Events
Subsequent to June 30, 2025, pursuant to a sales agreement dated November 13, 2024 with Guggenheim Securities, LLC, Unicycive Therapeutics, Inc. (the “Company”) sold 3,549,846 shares of common stock at an average price of $4.56 per share... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
- Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) |
| 08 Jul 2025 |
8-K: Other Events
--Nasdaq compliance follows reverse stock split previously announced on June 17, 2025 |
| 30 Jun 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis |
| 20 Jun 2025 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025 |
| 10 Jun 2025 |
8-K: Other Events
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis |
Loading...